Abstract
Fundamental and clinical studies were performed on ceftazidime (CAZ), a new cephem antibiotic.
1. Following a single intravenous administration of 1g dose of CAZ, the transfer of CAZ to the internal genital organs was good. The transfer of CAZ to retroperitoneal fluid was excellent.
2. In a clinical trial, CAZ was given to 6 patients with obstetrical and gynecological infections.
The efficacy was evaluated as excellent in 3 cases and good in the other 3 cases.
No adverse effects were observed in any of the patients treated with CAZ.
